Another Kratom NDI Fails—The Evidence Does Not Carry the Argument

There are submissions that invite debate. And then there are submissions where the record speaks plainly enough on its own.
The latest kratom New Dietary Ingredient (NDI) filing from TNT Manufacturing (d/b/a MitWellness), led by President Todd Underwood, belongs to the latter.

🧪 A Defined Extract, Not a Traditional Product

The ingredient is not vaguely described. It is specific:

“Mitragyna speciosa leaf extract standardized to 75 ± 3.5% mitragynine”

That is a standardized, high-concentration extract. Yet much of the safety narrative relies on traditional use—tea and raw leaf—where exposure is lower, less concentrated, and far less controlled.
That difference is acknowledged. It is not resolved.

📋 The Submission Was Not Complete

FDA first identified a basic issue: the record itself. Required references were missing, some citations were provided only as abstracts, and FDA had to request full supporting materials to complete the submission. That is not a disagreement over interpretation — it is a question of whether the evidence was fully presented at all.

⛔ The Core Problem: The Evidence Doesn’t Match the Product

In its final response, FDA does not hedge. It states that:

• Identity of the ingredient could not be established
• Safety could not be established
• The submission lacked adequate manufacturing detail, analytical verification, and linkage between studied materials and the actual product

Most notably, FDA explains:
“It is unclear how the product being marketed is qualitatively and quantitatively similar to the materials cited as evidence of safety.”
That is not a minor gap. That is the argument.

⚠️ The Conditions of Use Tell Their Own Story

Even the proposed labeling reflects the tension:

• Use limited to no more than 28 days
• Maximum 150 mg mitragynine per day
• Excludes pregnant or nursing individuals, and those with preexisting conditions
• Requires caution with CNS-active substances and CYP3A4-metabolized drugs
• Advises consultation with a healthcare professional

This is not presented as casual, general use. It is use with constraints, exclusions, and warnings.

🔬 The Pharmacology Is Not Disputed

The submission itself describes:

• Activity at the µ-opioid receptor
• Effects across dopamine, serotonin, and adrenergic systems
• Metabolism through major drug-interaction pathways (CYP3A4, etc.)

It also acknowledges tolerance, dependence, and withdrawal symptoms resembling opioids. These are not criticisms — they are statements from the submission itself.

📊 The Safety Record Is Not Empty

The filing includes case reports involving liver injury, neurologic effects, respiratory complications, renal injury, and death. It appropriately notes limitations — polysubstance use, incomplete data, uncertain causation. But the pattern of reported outcomes remains part of the evidence being presented.

💥 Where the Argument Fails

Taken piece by piece, each issue might be debated. Taken together, the problem is harder to avoid:

• A highly concentrated extract supported by lower-dose traditional use
• A submission FDA had to ask to complete
• A failure to establish what the ingredient is, how it was made, and how it relates to the cited evidence
• A pharmacologic profile consistent with a systemically active compound

At some point, the difficulty is no longer technical. It is structural.

📜 The FDA’s Conclusion — In Plain Terms

FDA’s final determination is not ambiguous:

• The submission does not provide an adequate basis to conclude safety
• A product containing this ingredient may be considered adulterated
• And critically: introduction of such a product into interstate commerce is prohibited under federal law

That is not a suggestion. It is a statutory bar. Any attempt to sell this 75% mitragynine extract across state lines would violate the Federal Food, Drug, and Cosmetic Act.

📉 Bottom Line

This is not a case where the evidence was weighed and found unpersuasive. It is a case where the evidence did not carry the argument it was asked to support. A 75% mitragynine extract was presented with a safety case built on something else — and FDA found that gap too large to bridge.

That is not a close call. It is a failed one.